Programme Thesis
Pharmacology 2026 is the British Pharmacological Society's annual meeting, a conference rather than a funding programme, designed to bring together pharmacologists to present cutting-edge research, network, and discuss advances across the field. It exists to foster scientific exchange, collaboration, and professional development within pharmacology, with a strong emphasis on translational and clinical relevance.
Selection Criteria
- Abstract scientific quality and novelty
- Relevance to pharmacology and the conference's thematic areas
- Clarity of hypothesis and experimental design
- Potential impact on the field or clinical practice
- For early-career researchers: alignment with BPS's mission to support the next generation
- Presentation quality (poster or oral) and engagement during the event
Past Winners / Cohort Profiles
As a conference, there are no 'winners' in the traditional grant sense, but past cohorts typically include academic researchers, clinicians, and industry scientists presenting posters and talks. Named examples are not listed on the page, but BPS annual meetings historically attract a mix of established professors, postdocs, and PhD students, with awards for best posters and presentations often given to early-career researchers.
Ideal Candidate Fingerprint
The ideal participant is a pharmacologist with a compelling, well-validated research finding that advances understanding of drug action or therapeutic intervention, presented clearly to a broad audience. They are likely affiliated with an academic or clinical institution, have a strong track record of rigorous methodology, and are eager to network and receive feedback from peers.
Recommended Framing
For Eniola, the strongest angle is to present the CCT model, as it directly addresses a core pharmacological question—how to prevent reward-memory encoding in addiction—using a rigorous, multi-scale computational approach that bridges molecular pharmacology and systems neuroscience. This aligns perfectly with the conference's focus on pharmacology and offers a unique, quantitative perspective that stands out from traditional experimental work. The abstract should emphasize the model's testable predictions and its potential to guide novel pharmacotherapies, leveraging Eniola's Bayesian calibration and pre-registered hypotheses to demonstrate scientific rigor.
Watch Out
None. As a conference, there are no strict eligibility barriers beyond registration and abstract submission. However, Eniola is an independent researcher without a formal academic affiliation at the time of submission (though enrolled in an M.Sc. starting 2026/27), which might be a minor consideration for some travel grants or awards, but not for standard participation.
Research History
2026-08-04 20:17 · medium confidence
2026-08-01 17:36 · medium confidence